Not available
Quote | Redhill Biopharma Ltd. (NASDAQ:RDHL)
Last: | $0.451 |
---|---|
Change Percent: | -1.32% |
Open: | $0.437 |
Close: | $0.451 |
High: | $0.4634 |
Low: | $0.437 |
Volume: | 221,058 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
News | Redhill Biopharma Ltd. (NASDAQ:RDHL)
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study PR Newswire First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat) 1 for early COVID-19 outpatient treatment, funded through non-...
2024-04-08 14:07:22 ET More on RedHill RedHill Biopharma looks to raise $1.25M in a direct offering of securities RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article o...
Message Board Posts | Redhill Biopharma Ltd. (NASDAQ:RDHL)
Subject | By | Source | When |
---|---|---|---|
RedHill's RHB-102 (BEKINDA) and Opaganib Granted New Patents | midastouch017 | investorshub | 05/01/2023 12:05:58 PM |
JOHANNESBURG, April 28, 2023 /PRNewswire/ --(NASDAQ: $RDHL) ("RedHill" | midastouch017 | investorshub | 04/28/2023 4:37:20 PM |
Whatever happened to the crohns disease drug? They | seve333 | investorshub | 04/28/2023 3:18:25 PM |
Discussions for potential commercialization partners are ongoing. | midastouch017 | investorshub | 04/28/2023 12:33:27 PM |
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results | midastouch017 | investorshub | 04/28/2023 12:26:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study PR Newswire First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat) 1 for early COVID-19 outpatient treatment, funded through non-...
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialt...